Press Releases

Date Title and Summary
Toggle Summary Soleno Therapeutics to Participate in the ROTH Battle of NASH Thrones Spring Investor Conference
REDWOOD CITY, Calif. , March 25, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar , M.D., Chief Executive Officer, will
Toggle Summary Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2018 Financial Results
REDWOOD CITY, Calif. , March 18, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update and announced financial results for the
Toggle Summary Soleno Therapeutics Announces Positive Outcome from Planned Data Safety Monitoring Board Review of Phase III DESTINY PWS Clinical Trial of DCCR in Prader-Willi Syndrome
REDWOOD CITY, Calif. --(BUSINESS WIRE)--Mar. 14, 2019-- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the Data Safety Monitoring Board (DSMB) has recommended the
Toggle Summary Soleno Therapeutics to Participate in Two Upcoming Investor Conferences
REDWOOD CITY, Calif. , March 11, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar , M.D., Chief Executive Officer, will
Toggle Summary Soleno Therapeutics Announces $16.5 Million Private Placement
Financing Led by Abingworth; Andrew Sinclair , Partner, to Join Soleno’s Board Funding to Support Ongoing Phase III Clinical Program (DESTINY PWS) for DCCR in Prader-Willi Syndrome REDWOOD CITY, Calif. , Dec. 19, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc.
Toggle Summary Soleno Therapeutics Presents Clinical Fat Loss Data on DCCR at the Obesity Society Meeting 2018
DCCR treatment resulted in statistically significant decreases in body fat in subjects with Prader-Willi Syndrome REDWOOD CITY, Calif. , Nov. 15, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the
Toggle Summary Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2018 Financial Results
REDWOOD CITY, Calif. , Nov. 15, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update and announced financial results for the third
Toggle Summary Soleno Therapeutics Presents Clinical Data on DCCR at 2018 Foundation for Prader-Willi Research Annual Conference
Oral presentation on DCCR’s mechanism of action in treating hyperphagia Poster presentation on DCCR’s safety profile and implications for PWS Phase III study design REDWOOD CITY, Calif. , Oct. 08, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage biopharmaceutical
Toggle Summary Soleno Therapeutics Presents Clinical Data on DCCR at Late-Breaking Session of European Society for Paediatric Endocrinology
Pharmacokinetic data supports once-daily dosing Long-term use of DCCR not associated with compromised glycemic control REDWOOD CITY, Calif. , Oct. 01, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the
Toggle Summary Soleno Therapeutics to Participate in Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease
REDWOOD CITY, Calif. , Sept. 19, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar , M.D., Chief Executive Officer, will conduct